Skip to main content

GT Biopharma Inc

Filed Jun 11, 2025.

View on SEC.gov

About this filing

A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.

period unavailable · Filed Jun 11, 2025

GTBP$4.42-2.6%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

EXPERTS

The consolidated balance sheets of GT Biopharma, Inc. as of December 31, 2024 and 2023, and the related consolidated statements of comprehensive loss, stockholders’ equity (deficit) and cash flows of GT Biopharma, Inc. for the years ended December 31, 2024 and 2023, incorporated by reference in this prospectus have been so incorporated in reliance on the reports of Weinberg and Company, P.A., an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

PRELIMINARY PROSPECTUS

120,553,632 Shares of Common Stock

The date of this prospectus is , 2025.

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 13. Other Expenses of Issuance and Distributions

The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the SEC registration fee.

SEC registration fee$54,321.94
FINRA filing fee$*
Accounting fees and expenses$10,000
Legal fees and expenses$150,000
Miscellaneous$*
Total$*
  • These fees are calculated based on the securities offered and the numbers of issuances and accordingly cannot be determined at this time.

Item 14. Indemnification of Directors and Officers

Section 145 of the DGCL provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee or agent to us. The DGCL provides that Section 145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise. Our certificate of incorporation provides for indemnification by us of our directors, officers and employees to the fullest extent permitted by the DGCL.

Section 102(b)(7) of the DGCL permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) for unlawful payments of dividends or unlawful stock repurchases, redemptions or other distributions or (iv) for any transaction from which the director derived an improper personal benefit. Our certificate of incorporation provides for such limitation of liability.

We have entered into separate indemnification agreements with our directors and executive officers.

Item 15. Recent Sales of Unregistered Securities

Since January 1, 2022, the Company made the following issuances of its unregistered securities pursuant exemptions contained in Section 4(a)(2) or 3(a)(9) of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder:

●Since January 1, 2022, we have issued 29,935 shares of Common Stock with a fair value of approximately $1,053,000 in connection with compensation of the Company’s officers and directors.
●·On August 24, 2022, the Company entered into a revised agreement with this third-party manufacturer and issued 40,742 shares of Common Stock with a fair value of approximately $3.2 million as part of a payment arrangement.
●·During the year ended December 31, 2022, the Company issued 11,257 shares of Common Stock upon conversion of notes payable.
●During the year ended December 31, 2022, the Company issued 23,654 shares of Common Stock to officers, employees, and Board with a fair value of approximate $2.5 million. This included 12,602 shares with a fair value of $938,000 that were granted during the year.
●During the year ended December 31, 2022, the Company issued 17,562 shares of Common Stock to consultants with a fair value of approximately $2.1 million.
●·During the year ended December 31, 2022, the Company issued 57,437 shares of Common Stock to settle approximately $700,000 of vendor payables.
●·During the year ended December 31, 2023, the Company issued 14,237 shares of Common Stock to officers, employees, and Board with a fair value of approximate $267,000. This included 13,333 shares with a fair value of $115,000 that were granted during the year.
●During the year ended December 31, 2023, the Company issued 1,545 shares of Common Stock to consultants with a fair value of approximately $162,000.
●·On January 4, 2023, the Company entered into a purchase agreement signed on December 30, 2022, between the Company and an institutional investor for the issuance and sale, in a registered direct offering of 120,000 shares of the Company’s Common Stock, pre-funded warrants to purchase up to 96,667 shares of the Company’s Common Stock, warrants to purchase up to an aggregate of 216,667 shares of the Company’s Common Stock and placement agent warrants to purchase up to 13,000 of the Company’s Common Stock. The Company raised $6.5 million from the offering.
●On April 30, 2024, the Company issued 36,018 shares of Common Stock to settle $278,500 of vendor accounts payable. The shares were valued at the month-end closing price of the Company’s Common Stock for the months for which services were provided by the vendor.
●On May 23, 2024, the Company issued 740,000 common warrants, each to purchase one share of Common Stock at an exercise price equal to $4.35 and are exercisable immediately upon issuance and will expire on the date that is five years following the date of issuance.
●·On May 23, 2024, the Company issued placement agent warrants to the placement agent to purchase up to 88,800 shares of Common Stock as part of the compensation payable to the placement agent in connection with such offering at an exercise price of $5.4375 per share and will expire five years from the commencement of sales of the offering.
●On June 30, 2024, the Company issued 91,579 shares of Common Stock to settle $531,300 of vendor accounts payable. The shares were valued at the month-end closing price of the Company’s Common Stock for the months for which services were provided by the vendor.
●On February 26, 2025, the Company issued (i) 302,069 common warrants, each to purchase one share of Common Stock at an exercise price equal to $2.02 and are exercisable immediately upon issuance and will expire on the date that is five years following the date of issuance, (ii) 302,069 common warrants, each to purchase one share of Common Stock at an exercise price equal to $2.02 and are exercisable immediately upon issuance and will expire on the date that is eighteen months following the date of issuance, and (iii) placement agent warrants to the placement agent to purchase up to 21,145 shares of Common Stock at an exercise price equal to $2.8375.
●On March 31, 2025, the Company issued prefunded warrants underlying 326,251 shares of Common Stock to settle approximately $847,000 of vendor accounts payable. The shares were valued at the month-end closing price of the Company’s Common Stock for the months for which services were provided by the vendor.
●On May 12, 2025, the Company entered into a securities purchase agreement with the purchasers identified therein for the issuance and sale of (i) 6,612 shares of Series L Preferred Stock, (ii) warrants to purchase up to 3,235,978 shares of Common Stock equal to 100% of the shares of Common Stock issuable upon conversion of the shares of Seres L Preferred Stock, and (iii) warrants to purchase up to 11,756,406 of Common Stock equal to the number of Greenshoe Conversion Shares issuable upon exercise of the Greenshoe Right, with an aggregate stated value of $6.6 million, for an aggregate purchase price of $5.95 million.
●On May 13, 2025, the Company issued 50,000 shares of Common Stock and warrants underlying 50,000 shares of Common Stock at an exercise price equal to $2.50 to a vendor accounts as compensation for services.
●On May 15, 2025, the Company issued warrants underlying 24,390 shares of Common Stock at an exercise price equal to $2.46 to investors in return entering into a Consent and Waiver Agreement dated March 18, 2025.

Item 16. Exhibits and Financial Statement Schedules

(a)Exhibits

Exhibit Index

Exhibit Number · Exhibit Description · Form · Date · Number · File No. · Filed Herewith
3.1Restated Certificate of Incorporation as filed in Delaware September 10, 1996 and as thereafter amended through March 1, 200210-KSB04/01/023.A
3.2Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., dated February 9, 201110-K03/31/20113.2
3.3Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of July 19, 20178-K/A03/15/20183.1
3.4Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of February 10, 20218-K02/11/20213.1
3.5Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective June 13, 202210-K03/30/20233.5
3.6Amended and Restated Bylaws of GT Biopharma, Inc., effective November 3, 20228-K11/09/20223.1
3.7Certificate of Amendment of Restated Certificate of Incorporation of GT Biopharma, Inc., effective February 1, 20248-K02/01/20243.1
4.1Certificate of Designation of Preferences, Rights and Limitations of Series J-1 Preferred Stock of GT Biopharma, Inc., dated April 3, 20198-K04/04/20193.1
4.2Certificate of Designation of Preferences, Rights and Limitations of Series K Preferred Stock of GT Biopharma, Inc., dated February 22, 202110-K04/16/20214.2
4.3Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred Stock, dated May 12, 20258-K05/13/20253.1
4.4Certificate of Increase of the Designated Number of Shares of Series L 10% Convertible Preferred Stock, dated May 22, 20258-K05/27/20253.1
4.5Description of the Registrant’s Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934, as Amended10-K03/30/20234.3
4.6Form of 10% Senior Convertible Debenture (related to Securities Purchase Agreement, dated January 9, 2017)8-K01/13/201710.2
4.7Form of Common Stock Purchase Warrant (related to Securities Purchase Agreement, dated January 9, 2017)8-K01/13/201710.3
4.8Registration Rights Agreement, dated January 22, 2018, among GT Biopharma, Inc. and the buyers named therein8-K01/23/201810.2
4.9Form of Senior Convertible Note (related to Securities Purchase Agreement, dated January 22, 2018)8-K01/23/201810.3
4.10Form of Warrant to Purchase Common Stock (related to Securities Purchase Agreement, dated January 22, 2018)8-K01/23/201810.4
4.11Form of 10% Senior Convertible Debenture (related to Securities Purchase Agreement, dated August 2, 2018)8-K08/03/20184.1
4.12Form of 10% Senior Convertible Debenture (related to Securities Purchase Agreement, dated September 7, 2018)8-K09/07/20184.1
4.13Form of 10% Senior Convertible Debenture (related to Securities Purchase Agreement, dated September 24, 2018)8-K09/28/20184.1
Exhibit Number · Exhibit Description · Form · Date · Number · File No. · Filed Herewith
4.14Form of Secured Convertible Note (related to Securities Purchase Agreement, dated February 4, 2019)8-K02/06/20194.1
4.15Registration Rights Agreement, dated May 22, 2019, among GT Biopharma, Inc. and the purchasers named therein8-K05/24/201910.2
4.16Form of Convertible Note (related to Securities Purchase Agreement, dated August 20, 2019)8-K05/24/20194.1
4.17Registration Rights Agreement, dated August 20, 2019, among GT Biopharma, Inc. and the purchasers named therein8-K08/20/201910.2
4.18Form of Convertible Note (related to Securities Purchase Agreement, dated May 22, 2019)8-K05/24/20194.1
4.19Registration Rights Agreement, dated January 30, 2020, among GT Biopharma, Inc. and the purchaser named therein10-Q05/15/202010.2
4.20Registration Rights Agreement, dated January 30, 2020, among GT Biopharma, Inc. and the purchaser named therein10-Q05/15/202010.2
4.21Form of Convertible Note (related to Securities Purchase Agreement, dated January 30, 2020)10-Q05/15/202010.3
4.22Form of Registration Rights Agreement among GT Biopharma, Inc. and the purchaser named therein (executed in April/May 2020)10-Q05/15/202010.5
4.23Form of Convertible Note (related to Securities Purchase Agreement executed in April/May 2020)10-Q05/15/202010.6
4.24Registration Rights Agreement, dated July 7, 2020, among GT Biopharma, Inc. and the purchaser named therein8-K07/09/202010.3
4.25Form of Convertible Note (related to Securities Purchase Agreement, dated July 7, 2020)8-K07/09/20204.1
4.26Form of Convertible Note, dated June 19, 2020 (related to Settlement Agreement, dated June 19, 2020).8-K06/19/202010.2
4.27Form of Pre-Funded Warrant to Purchase Common Stock, dated June 19, 2020 (related to Settlement Agreement, dated June 19, 2020).8-K06/19/202010.3
4.28Form of Convertible Note (related to Securities Purchase Agreement, dated September 16, 2020)8-K09/22/20204.1
4.29Form of Secured Convertible Note8-K11/09/20204.1
4.30Form of Settlement Note, dated November 9, 2020.10-Q11/13/202010.20
4.31Settlement Note, dated December 22, 2020, by GT Biopharma Inc. payable to Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B.8-K12/28/202010.2
4.32Form of Amendment to Convertible Note, dated January 31, 20218-K02/01/202010.2
4.33Form of Common Warrant8-K01/03/20234.1
4.34Form of Pre-Funded Warrant8-K01/03/20234.2
4.35Form of Placement Agent Warrant8-K01/03/20234.3
4.36Form of Common Warrant8-K05/23/20244.1
4.37Form of Common WarrantS-1/A01/27/20254.35
4.38Form of Pre-Funded WarrantS-1/A01/27/20254.36
4.39Form of Placement Agent WarrantS-1/A01/27/20254.37
4.40Form of Series A Inducement Warrant8-K02/26/20254.1
4.41Form of Series B Inducement Warrant8-K02/26/20254.2
4.42Form of Inducement Placement Agent WarrantsS-303/06/20254.10
4.43Form of Prefunded Common Stock Warrant8-K04/04/20254.1
4.44Form of Common Warrant8-K05/13/20254.1
4.45Form of Vesting Warrant8-K05/13/20254.2
4.46Form of Prefunded Common Stock Purchase Warrant10-Q05/15/20254.6
4.47GT Biopharma, Inc. 2022 Omnibus Incentive PlanDEF 14A04/29/2022
5.1Opinion of Baker & Hostetler LLPS-15.1X
10.1Exclusive License Agreement, dated July 18, 2016, between the Regents of the University of Minnesota and Oxis Biotech, Inc.10-Q08/11/201710.3
10.2License Agreement, dated September 3, 2015, among Daniel A. Vallera, Jeffrey Lion and Oxis Biotech, Inc.10-Q08/11/201710.4
10.3Clinical Trial Agreement, dated September 2019, between the Regents of the University of Minnesota and GT Biopharma, Inc.10-Q05/15/202010.7
Exhibit Number · Exhibit Description · Form · Date · Number · File No. · Filed Herewith
10.4Securities Purchase Agreement, dated January 30, 2020, among GT Biopharma, Inc. and the purchaser named therein10-Q05/15/202010.1
10.5Form Securities Purchase Agreement among GT Biopharma, Inc. and the purchaser named therein (executed in April/May 2020)10-Q05/15/202010.4
10.6Securities Purchase Agreement, dated July 7, 2020, among GT Biopharma, Inc. and the purchaser named therein8-K07/09/202010.1
10.7Form of Standstill and Forbearance Agreement, dated June 23, 2020, between the Company and certain holders of convertible notes and debentures8-K06/23/202010.1
10.8Settlement Agreement, dated June 19, 2020, among GT Biopharma, Inc., Empery Asset Master Ltd., Empery Tax Efficient, LP and Empery Tax Efficient II, LP, Anthony Cataldo and Paul Kessler.8-K06/19/202010.1
10.9Executive Employment Agreement, dated October 19, 2018, among GT Biopharma, Inc. and Raymond W. Urbanski10-Q11/14/201810.17
10.10Consultant Agreement, dated February 14, 2018, among GT Biopharma, Inc., Georgetown Translational Pharmaceuticals, Inc. and Anthony J. Cataldo8-K02/21/201810.3
10.11Employment agreement with Anthony Cataldo10-Q08/14/202010.11
10.12Employment agreement with Steven Weldon10-Q08/14/202010.12
10.13Securities Purchase Agreement, dated September 16, 2020, among GT Biopharma, Inc. and the purchasers named therein8-K09/22/202010.1
10.14Master Services Agreement, dated October 5, 2020, between Gt Biopharma, Inc. and Cytovance Biologics, Inc.8-K10/06/202010.1
10.15Form of First Amendment and Extension of Standstill and Forbearance Agreement8-K11/04/202010.1
10.16Securities Purchase Agreement8-K11/09/202010.1
10.17Settlement Agreement, dated as of November 9, 2020, by and among Adam Kasower, East Ventures, Inc., A British Virgin Islands company, SV Booth Investments III, LLC, a Delaware limited liability company and Theorem Group, LLC, a California LLC and GT Biopharma Inc., a Delaware corporation.10-Q11/13/202010.19
10.18Steve Weldon Letter of Resignation, dated November 11, 202010-Q11/13/202010.21
10.19Board Service Agreement with Bruce Wendel, dated November 11, 202010-Q11/13/202010.22
10.20Board Service Agreement with Greg Berk, dated November 11, 202010-Q11/13/202010.23
10.21Consultant Agreement with Michael Handelman, dated November 13, 202010-Q11/13/202010.24
10.22Form of Amendment to Convertible Note & Standstill Agreement8-K12/23/202010.1
10.23Settlement Agreement, dated as of December 22, 2020, by and among Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, Anthony Cataldo, Paul Kessler and GT Biopharma Inc., a Delaware corporation.8-K12/28/202010.1
10.24Form of Second Amendment and Extension of Standstill and Forbearance Agreement.8-K02/01/202010.1
10.25Board Service Agreement with Rajesh Shrotriya, dated January 12, 2021.S-1/A02/08/202110.69
Exhibit Number · Exhibit Description · Form · Date · Number · File No. · Filed Herewith
10.26Board Service Agreement with Michael Breen, dated January 12, 2021.S-1/A02/08/202110.70
10.27Amendment to Settlement Note with Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B.S-1/A02/08/202110.71
10.28Form of Securities Purchase Agreement - December 2020 / January 2021 NotesS-1/A02/08/202110.72
10.29Form of December 2020 / January 2021 NoteS-1/A02/08/202110.73
10.30Amended and Restated Employment Agreement with Anthony Cataldo, dated April 23, 2021.10-Q05/17/202110.1
10.31Amended and Restated Employment Agreement with Michael Handelman, dated April 23, 2021.10-Q05/17/202110.2
10.32Amended and Restated Employment Agreement with Dr. Gregory Berk, dated April 23, 202110-Q05/17/202110.3
10.33Exclusive License Agreement with Regents of the University of Minnesota, dated March 26, 202110-K03/28/202210.73
10.34Research Agreement with Regents of the University of Minnesota, dated June 16, 2021.10-K03/28/202210.74
10.35Sublease Agreement dated November, 2021, between Aimmune Therapeutics, Inc. (Sublandlord) and GT Biopharma, Inc. (Subtenant)10-K03/28/202210.75
10.36Employment Agreement with Michael Breen, entered into as of December 31, 2021 with an effective date of November 8, 202110-K03/28/202210.76
10.37Amendment No. 1 to Employment Agreement with Michael Breen, dated as of June 17, 2022.10-K03/26/202410.77
10.38Amendment No. 2 to Services Agreement with Michael Breen, dated as of February 20, 2023.10-K03/26/202410.78
10.39Board Service Agreement with Michael Breen dated November 11, 202010-Q05/16/202210.1
10.40Employment Agreement with Manu Ohri dated May 15, 202210-Q05/16/202210.2
10.41Amendment No. 1 to Employment Agreement with Manu Ohri, dated as of February 17, 202310-K03/26/202410.81
10.42Settlement and Investment Agreement dated August 24, 2022, by and between GT Biopharma, Inc. and Cytovance Biologics, Inc.10-Q10/31/202210.1
10.43Form of Securities Purchase Agreement, dated December 2022, by and between GT Biopharma, Inc. and the purchasers named therein.8-K01/03/202310.1
10.44Amendment No. 1 to Settlement and Investment Agreement, dated as of April 25, 2024, by and between GT Biopharma, Inc. and Cytovance Biologics, Inc.8-K04/30/202410.1
10.45Amended and Restated Exclusive Patent License Agreement with the Regents of the University of Minnesota, dated May 13, 202410-Q04/30/202410.2
10.46Sponsored Research Agreement with the Regents of the University of Minnesota dated May 20, 202410-Q04/30/202410.3
10.47Form of Securities Purchase Agreement8-K05/23/202410.1
10.48Form of Placement Agency Agreement8-K05/23/202410.2
10.49Code of Ethics10-K03/31/201514.1
10.50Investigator Initiated Clinical Trial Agreement8-K11/18/202410.1
10.51Form of Securities Purchase AgreementS-1/A01/27/202510.51
10.52Form of Placement Agency AgreementS-1/A01/27/202510.52
10.53Employment Agreement between the Company and Alan Urban, dated as of June 7, 20248-K06/07/202410.1
10.54Form of Inducement Letter8-K02/26/202510.1
10.55Securities Purchase Agreement, dated as of May 12, 2025, between the Company and the purchasers identified therein.8-K05/13/202510.1
10.56First Amendment to Securities Purchase Agreement, dated as of May 21, 2025, between the Company and the purchasers identified therein.8-K05/27/202510.1
10.57Registration Rights Agreement, dated as of May 12, 2025, between the Company and the purchasers identified therein.8-K05/13/202510.2
10.58Joinder to Registration Rights Agreement, dated as of May 21, 2025, between the Company and the purchaser identified therein.8-K05/27/202510.2
10.59Form of Voting Agreement8-K05/13/202510.3
10.60Form of Lock-Up Agreement8-K05/13/202510.4
10.61Common Shares Purchase Agreement, dated as of May 14, 2025, between the Company and the investors identified therein.10-Q05/15/202510.2
10.62First Amendment to Common Shares Purchase Agreement, dated as of June 10, 2025, between the Company and the investors identified therein.8-K06/11/202510.1
21.1Subsidiaries of GT Biopharma, Inc.10-K03/31/201521.1
23.1Consent of Weinberg & CompanyX
23.2Consent of Baker & Hostetler LLP (incl. in Exhibit 5.1)X
24.1Power of AttorneyX
101.INSXBRL Instance DocumentX
101.SCHXBRL Taxonomy Extension Schema DocumentX
101.CALXBRL Taxonomy Extension Calculation Linkbase DocumentX
101.DEFXBRL Taxonomy Extension Definition Linkbase DocumentX
101.LABXBRL Taxonomy Extension Label Linkbase DocumentX
101.PREXBRL Taxonomy Extension Presentation Linkbase DocumentX
107Filing Fee TableX
†Confidential treatment granted from the SEC as to certain portions, which portions have been omitted and filed separately with the SEC.
+Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. GT Biopharma, Inc. will furnish copies of any such schedules to the SEC upon request.
**To be filed by amendment.

Item 17. Undertakings

The undersigned Registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement to:

(i) include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii) reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement; and

(iii) include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

*provided, however,*that paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initialbona fideoffering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

(i) Each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

(ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initialbona fideoffering thereof.Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

(5) That, for the purpose of determining liability of the Registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned Registrant undertakes that in a primary offering of securities of the undersigned Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned Registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

(i) Any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;

(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant;

(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned Registrant or its securities provided by or on behalf of the undersigned Registrant; and

(iv) Any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.

(6) That, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initialbona fideoffering thereof.

Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended (the “Securities Act”), may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Los Angeles, State of California, on June 11, 2025.

GT Biopharma Inc.
Date: June 11, 2025By:/s/ Michael Breen
Michael Breen
Chief Executive Officer
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.